廖永红，中国医学科学院药用植物研究所制剂中心副主任，研究员，博士生导师。先后就读于清华大学化学系、中国协和医科大学研究生院和英国伦敦大学国王学院药学系。2003年9月至今在药用植物研究所工作，主要从事肺部吸入给药系统和天然产物生物药剂学等方向研究。曾先后主持或分课题主持了国家自然基金、十一五科技支撑计划、北京市自然基金国家、重大新药创制等课题10多项，发表论文100多篇，其中80多篇为SCI收录，申报了8项专利。

邮箱 : yhliao@implad.ac.cn

工作电话 : 010-57833268

主要研究项目

1. 中国医学科学院医学与健康科技创新工程重大协同创新项目：急性呼吸道感染的抗病毒和宿主个体化干预新策略研究。（2021.10-2025.12）

2．国家自然基金面上项目：中药注射液的肺部生物药剂学评价及适宜肺部吸入制剂技术研究。（2022.1-2025.12）

3. 重大新药创制国家科技重大专项项目：基于动物行为实验的抗抑郁药效评价指标体系及参远苷抗抑郁临床前研究（2017.1-2020.12）

4. 重大新药创制国家科技重大专项项目—基于中药生物药剂学分类系统构建提高中药成药性制剂技术平台（2015.1-2019.12）。

5. 国家自然科学基金青年项目：新型肠道Ⅱ相代谢调控自微乳制剂及其机理研究。（2017.1-2019.12）

近5年代表性论文

1. Jia-Xing Wei,Chao-Yi Li, Wei-Ya Chen, Yi-Jun Cong, Chun-Yu Liu, Fei-Fei Yang*, Yong-HongLiao*. The pulmonary biopharmaceutics and anti-inflammatory effects afterintratracheal and intravenous administration of Re-Du-Ning injection. BiomedPharmacother. 2023; 160:114335.

2. Cong Yi-Jun,Chen Wei-Ya, Wei Jia-Xing, Liu Chun-Yu, Yang Fei-Fei*, Liao Yong-Hong*. Thepulmonary pharmacokinetics and anti-inflammatory effects after intratrachealand intravenous administration of Chuankezhi injection. Biomed Pharmacother.2022; 156:113892.

3. Siqi Ma,Zhaoqing Cong, Jiaxing Wei, Weiya Chen, Di Ge, Feifei Yang*, Yonghong Liao*.Pulmonary delivery of size-transformable nanoparticles improves tumoraccumulation and penetration for chemo-sonodynamic combination therapy. JControl Release. 2022; 350:132-145.

4. Siqi Ma,Zhaoqing Cong, Huan Chen, Han Wen, Li Cao, Chunyu Liu, Feifei Yang*, YonghongLiao*. Velvet antler polypeptide-loaded polyvinyl alcohol-sodium alginatehydrogels promote the differentiation of neural progenitor cells in 3D towardsoligodendrocytes in vitro. Eur J Pharm Sci. 2021; 167:106003.

5. Yan Zhang,Fei-Fei Yang, Huan Chen, Yao-Dong Qi, Jian-Yong Si, Qing Wu*, Yong-Hong Liao*.Analysis of pyrrolizidine alkaloids in Eupatorium fortunei Turcz. and their invitro neurotoxicity. Food Chem Toxicol. 2021; 151:112151.

6. Chen Wei-Ya,Yang Fei-Fei, Li Cui, Li Wen-Hui, Hu Jie, Liao Yong-Hong*. Comparison of plasmaand pulmonary availability of chlorogenic acid, forsythiaside A and baicalinafter intratracheal and intravenous administration of Shuang-Huang-Lianinjection. J Ethnopharmacol. 2021; 274:114082.

7. Yang FF, MedikY, Li LT, Tian X, Fu D, Brouwer KLR, Wagner K, Sun B, Sendi H, Mi Yu*, WangAZ*. Nanoparticle drug delivery can reduce the hepatotoxicity of therapeuticcargo. Small. 2020, e1906360. doi: 10.1002/smll.201906360.

8. Zhaoqing Cong,Lu Zhang, Si-Qi Ma, Kit S. Lam, Fei-Fei Yang*, Yong-Hong Liao*.Size-transformable hyaluronan stacked self-assembling peptide nanoparticles forimproved transcellular tumor penetration and photo-chemo combination therapy.ACS Nano. 2020;14(2):1958-1970.

9. Wei-Ya C,Yuan-Song W, Chun-Yu L, Yu-Bin J, Fei-Fei Y*, Yong-Hong L*. Comparison ofpulmonary availability and anti-inflammatory effect of dehydroandrographolidesuccinate via intratracheal and intravenous administration. Eur J Pharm Sci.doi: 10.1016/j.ejps.2020.105290.

10. Mi Y, Yang F,Bloomquist C, Xia Y, Sun B, Qi Y, Wagner K, Montgomery SA, Zhang T, Wang AZ.Biologically Targeted Photo-Crosslinkable Nanopatch to Prevent PostsurgicalPeritoneal Adhesion. Adv Sci (Weinh). 2019, 6(19):1900809.

11. Fu TT, CongZQ, Zhao Y, Chen WY, Liu CY, Zheng Y, Yang FF*, Liao YH*. Fluticasonepropionate nanosuspensions for sustained nebulization delivery: An in vitro andin vivo evaluation. Int J Pharm. 2019, 572:118839.

12. Cong Z, ZhouM, Yang F, Liu C, Pan R, Chang Q, Liu X, Liao Y. Effects of Ganoderma, Rhodiolaand grape seed extracts on the glucuronidation and oral bioavailability ofresveratrol in rats. Nat Prod Res. 2019, 33(5):767-771.

13. Fei-Fei Yang,Ci-Yu Ji, Zhao-Qing Cong, Si-Qi Ma, Chun-Yu Liu, Rui-Le Pan, Qi Chang, Yu-BinJi, Yong-Hong Liao*. Enhancing in vivo oral bioavailability of cajaninstilbeneacid using UDP-glucuronosyl transferase inhibitory excipient containingself-microemulsion. Colloids Surf B Biointerfaces. 2020;93:111069.

14. Mi Y, SmithCC, Yang F, Qi Y, Roche KC, Serody JS, Vincent BG, Wang AZ. A DualImmunotherapy Nanoparticle Improves T-Cell Activation and Cancer Immunotherapy.Adv Mater. 2018, 30(25):e1706098.

15. Fu TT, Zhao Y,Yang FF, Wen H, Liu CY, Liao YH. Ciclesonide and budesonide suspensions fornebulization delivery: An in vivo inhalation biopharmaceutics investigation.Int J Pharm. 2018, 549(1-2): 21-30.

16. Yang FF, ZhouJ, Hu X, Cong ZQ, Liu CY, Pan RL, Chang Q, Liu XM, Liao YH. Improving oralbioavailability of resveratrol by a UDP-glucuronosyltransferase inhibitoryexcipient-based self-microemulsion. Eur J Pharm Sci. 2018, 114:303-309.

17. Zhang M, HaganCT 4th, Min Y, Foley H, Tian X, Yang F, Mi Y, Au KM, Medik Y, Roche K, WagnerK, Rodgers Z, Wang AZ. Nanoparticle co-delivery of wortmannin and cisplatinsynergistically enhances chemoradiotherapy and reverses platinum resistance inovarian cancer models. Biomaterials. 2018, 169:1-10.

18. Chang Y, YangF, Wen H, Fu T, Liu C, Quan L. The effect of L-leucine on the stabilization andinhalability of spray-dried solid lipid nanoparticles for pulmonary drugdelivery. J Drug Deliv Sci Tec. 2018, 46:474-481.

       专利：

        1.药物可吸入微粒、使用其的肺部吸入制剂及其制备方法。专利号：ZL200710177322.3。

        2.中药提取物的防潮方法及得到的中药固体制剂。专利号：ZL201210265186.4。

        3.一种人参水解产物PPT/PPD的自微乳软胶囊及其制备方法。专利号：ZL201510435274.8。

        4.一种负载20（S）-原人参二醇的固体分散体及其制备方法和应用。申请号：202111363133.1。

        5.一种供肺部吸入使用的药物缓释制剂及其制备方法与应用。申请号：202211680442.6。

        6.淫羊藿黄酮雾化吸入制剂及其应用。申请号：202211007840.1。申请号：202211007840.1。